Heparanase is a prognostic indicator for postoperative survival in pancreatic carcinoma

por Rohloff, J, Zinke, J, Schoppmeyer, K, Tannapfel, A, Witzigmann, H, Mössner, J, Wittekind, C, Caca, K
Publicado 2002

Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma

por Rohloff, J, Zinke, J, Schoppmeyer, K, Tannapfel, A, Witzigmann, H, Mössner, J, Wittekind, C, Caca, K
Publicado 2002

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

por Atmaca, A, Al-Batran, S-E, Werner, D, Pauligk, C, Güner, T, Koepke, A, Bernhard, H, Wenzel, T, Banat, A-G, Brueck, P, Caca, K, Prasnikar, N, Kullmann, F, Günther Derigs, H, Koenigsmann, M, Dingeldein, G, Neuhaus, T, Jäger, E
Publicado 2013

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic co...

por Heinrich, K., Karthaus, M., Fruehauf, S., Graeven, U., Mueller, L., König, A.O., von Weikersthal, L. Fischer, Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Alig, A.H.S., Kurreck, A., Stahler, A., Held, S., Sommerhäuser, G., Heinemann, V., Stintzing, S., Trarbach, T., Modest, D.P.
Publicado 2023